Civica Invests $27.8 Million for a New Testing Facility
Civica, Inc. (Lehi, Utah, USA), a nonprofit generic drug company, will invest $27.8 million to establish a new laboratory testing facility at Meadowville Technology Park in Chesterfield County, Virginia, USA. The company will construct a 55,000-square-foot facility to support its Petersburg, Virginia, pharmaceutical manufacturing operation through quality testing and development of new products. The project will create 51 new jobs.
The construction of the laboratory will be supported by an award from the U.S. Economic Development Administration to the Alliance for Building Better Medicine, a coalition that aims to expand essential medicines manufacturing in the Richmond-Petersburg region. Civica will provide matching capital.
Civica is a nonprofit generic drug company launched in 2018 to address the problem of chronic generic drug shortages and high drug prices. The company’s new laboratory testing facility in Chesterfield County is expected to be operational soon after the Petersburg plant reaches commercial scale in 2024.
For more information, please visit: www.civicarx.org
LC–MS/MS Quantification of Plasma Proteins in Elephant Seals to Advance Wildlife Conservation
November 12th 2024Liquid chromatography and tandem mass spectrometry (LC–MS/MS) was used to show that repeated stress can cause delayed but sustained changes in blood plasma proteins associated with water conservation, immune responses, fat metabolism, insulin sensitivity, iron recycling, and hormone transport in elephant seals. Some of these changes may be novel markers of recent and chronic stress exposure in marine mammals.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
